Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.
Receptors that bind the active ingredient in marijuana may be novel therapeutic targets in autoimmune disease, but contested evidence for their presence on neurons could hamper drug development
This year’s Nobel Prizes; toward developing a brown fat-activating drug; certain antioxidants can increase the spread of melanoma in mice; anonymity and post-publication peer review